Literature DB >> 21306809

Silenced voices: Israeli mothers' experience of feticide.

Ronit D Leichtentritt1.   

Abstract

The study is a qualitative analysis of 13 interviews with Israeli women who experienced feticide by injection at a late stage of their pregnancy due to fetus abnormality. Neither the public nor health care professionals are fully aware of the implications and significance of feticide to the mother. The goal of this study which was conducted from May 2008 until October 2009 was to understand and give voice to the women's experience. Three themes were discovered: (a) difficult decision making process and outcomes; (b) the unbearable experience of feticide; and (c) feticide as an unspoken experience. Feticide was revealed to incorporate both social and psychological layers; thus, the findings highlight the interface between a personal experience and a social phenomenon. The women's experience is discussed within the Israeli social context, where feticide is a relatively common yet unspoken procedure.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21306809     DOI: 10.1016/j.socscimed.2010.12.021

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  3 in total

1.  The 2015 Pregnancy Summit, London, UK.

Authors:  Cherynne Johansson
Journal:  Womens Health (Lond)       Date:  2016-02-22

2.  Termination of pregnancy for fetal anomaly: a systematic review of the healthcare experiences and needs of parents.

Authors:  Suzanne Heaney; Mark Tomlinson; Áine Aventin
Journal:  BMC Pregnancy Childbirth       Date:  2022-05-26       Impact factor: 3.105

3.  Parental decision-making following a prenatal diagnosis that is lethal, life-limiting, or has long term implications for the future child and family: a meta-synthesis of qualitative literature.

Authors:  Claire Blakeley; Debbie M Smith; Edward D Johnstone; Anja Wittkowski
Journal:  BMC Med Ethics       Date:  2019-08-08       Impact factor: 2.652

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.